IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study

High Blood Pressure Clinical Trial

— IMPULSION  

Official title:

IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00416611
• Other study ID #: HAS-02-231206
• Status: Completed
• Phase: Phase 4
• First received: December 23, 2006
• Last updated: January 28, 2009
• Start date: November 2006
• Est. completion date: November 2007

Study information

• Verified date: January 2009
• Source: Hellenic Atherosclerosis Society
• Contact: n/a
• Is FDA regulated: No
• Health authority: Greece: Ministry of Health and Welfare
• Study type: Observational

Clinical Trial Summary

The objective of this protocol is to improve awareness, treatment, and control of arterial hypertension, within primary prevention of target organ damage, by implementing guidelines, after training of the participating physicians.

Description:

Physicians from 20 hospitals and 40 health centres (primary health care settings) were trained to implement guidelines in treating arterial hypertension.

There will be a baseline recording of patients with arterial hypertension and then physicians will have to complete a one page form (by ticking pre-specified boxes) about the baseline status of the patients and will have to report the measures they took to improve awareness, treatment, and effective control of arterial hypertension. After a six month effort, physicians will have to complete the same form at study completion. Previous training of physicians and the fact that they will have to report their success in treating hypertension will hopefully contribute to an increase in number of hypertensive patients at blood pressure target, and will minimise the target organ damage. The estimated reduction in coronary heart disease risk will be evaluated by a comparison of this risk (as evaluated by a risk engine, i.e. PROCAM) at study completion with that of baseline.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1000
• Est. completion date: November 2007
• Est. primary completion date: November 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Arterial hypertension as defined by the JNC 7 report

Exclusion Criteria:

• Pregnancy

• Lactation

• Malignancies with small life expectancy

• Unwillingness to participate

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• High Blood Pressure
• Hypertension

Intervention

Behavioral:
• Implementation of guidelines

Locations

Country	Name	City	State
Greece	Hellenic Atherosclerosis Society	Thessaloniki

Sponsors (1)

Lead Sponsor	Collaborator
Hellenic Atherosclerosis Society

Country where clinical trial is conducted

Greece, 

References & Publications (1)

Karagiannis A, Athyros VG, Papageorgiou A, Tziomalos K, Elisaf M. Should atenolol still be recommended as first-line therapy for primary hypertension? Hellenic J Cardiol. 2006 Sep-Oct;47(5):298-307. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy in arterial hypertension control		6 months	No
Primary	Efficacy in reducing estimated risk of coronary heart disease		6 months	No
Secondary	Cost effectiveness of arterial hypertension control		6 months	No
Secondary	Differences between primary and secondary health care settings as well as teaching hospitals		6 months	No